Radiopharmaceutical therapy delivers promising meningioma survival rates
The Phase II clinical trial is the first completed prospective trial for refractory meningiomas with a tumour growth rate of 15 percent or more over six months.
List view / Grid view
The Phase II clinical trial is the first completed prospective trial for refractory meningiomas with a tumour growth rate of 15 percent or more over six months.
An “innovative, life-extending treatment” for BRAF V600E mutation-positive glioma has been recommended for certain young people on the NHS.
“Injecting a virus into a patient’s brain tumour” combined with immunotherapy improved glioblastoma survival outcomes in a clinical trial.
A novel ultrasound technique opened the blood-brain barrier to successfully deliver chemotherapy to glioblastoma patients in a first-in-human trial.
Research for rare diseases including ALS will be supported over the next four years by $38 million in FDA funding.
A study has shown that PBAE nanoparticles could replace viral vectors in gene therapies and provide a safe treatment option for paediatric brain cancer patients.
Children with an extremely deadly form of brain cancer may benefit from a new treatment that aims to direct an immune response against an abnormally shaped protein found on cancer cells...
Arsenic trioxide could extend the survival of glioblastoma patients by three to four times the historic median...
Mvasi, a biosimilar to the cancer drug Avastin, is approved for certain colorectal, lung, brain, kidney and cervical cancers…
17 June 2013 | By Roche
First approval of Avastin for the treatment of newly diagnosed glioblastoma...